Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19079810 | 0.68 | SLC6A3 (0.37) | HSD17B10MAPTSMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL9242569 | 0.67 | NPSR1 (0.46) | NPSR1TSHRCA1CA2CA12 | |
| SCHEMBL11755388 | 0.67 | NPSR1 (0.46) | NPSR1TSHRCA1CA2CA12 | |
| SCHEMBL5607056 | 0.67 | NPSR1 (0.46) | NPSR1TSHRCA1CA2CA12 | |
| SCHEMBL9063074 | 0.67 | NPSR1 (0.46) | NPSR1TSHRCA1CA2CA12 | |
| SCHEMBL498036 | 0.67 | — | — | |
| SCHEMBL11755378 | 0.67 | NPSR1 (0.46) | NPSR1TSHRCA1CA2CA12 | |
| SCHEMBL18855912 | 0.64 | HPGD (0.34) | NPSR1TSHRCA1CA2CA12 | |
| SCHEMBL498203 | 0.63 | — | — | |
| SCHEMBL2131145 | 0.63 | SLC6A3 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4582578-A | Method for the electrochemical conversion of a quadricyclane to a norbornadiene | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1986-04-15 | — | — | US | claimed |
| EP-3749674-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369697-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-11-26 | — | — | US | disclosed |
| WO-2019157376-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-08-15 | — | — | WO | disclosed |
| US-9441059-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-13 | — | — | US | disclosed |
| US-9315604-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140378637-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL SCIENCE FOUNDATION | 2014-12-25 | — | — | US | disclosed |
| US-20140330018-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140309388-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014169014-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-16 | — | — | WO | disclosed |
| US-8546500-B2 | Complexes for use in metathesis reactions | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120302710-A1 | COMPLEXES FOR USE IN METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-29 | — | — | US | disclosed |
| US-6569600-B2 | Optical apparatus comprising binders, sensitizers and reactants capable of undergoing rearrangements when exposed to actinic radiation causing optical changes such as refractive index | EASTMAN KODAK COMPANY | 2003-05-27 | — | — | US | disclosed |
| US-20030072250-A1 | When exposed to actinic radiation produces a change in optical properties in the exposed region, contains a binder, a reactant capable of undergoing a transformation upon an electrone oxidation, and a sensitizer | EASTMAN KODAK COMPANY | 2003-04-17 | — | — | US | disclosed |
| EP-1246179-A2 | Optical recording material | EASTMAN KODAK COMPANY (US) | 2002-10-02 | — | — | EP | disclosed |
| US-5081088-A | Preparing propylene polymers | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302710-A1 | COMPLEXES FOR USE IN METATHESIS REACTIONS | APEX1, SOD1, PMS2 | NPSR1 2186/4885TSHR 4265/4885CA1 471/4885 |
| US-20200369697-A1 | MOLYBDENUM OXO ALKYLIDENE COMPOUNDS, METHODS OF MAKING THE SAME AND USE THEREOF IN METATHESIS REACTIONS | MSRB3, MMAB, CYB5R3 | NPSR1 1942/4885TSHR 2953/4885CA1 2956/4885 |
| US-20140330018-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | TERT, CYP19A1, MPO | NPSR1 2571/4885TSHR 4706/4885CA1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.